Given the wide range of effects (antioxidant, anti-inflammatory, renin-angiotensin-system inhibitory, antibacterial, antiviral, antifungal) of lactoferrin, lysozyme, and ovotransferrin proteins in the supplement and evidence for the benefit of these proteins in various disease models (e.g., hypertension [65], inflammatory bowel disease [30,66], peritonitis [36], Alzheimer's disease [67]), coupled with the good adherence and safety of the study supplement, there is justification to investigate the therapeutic potential in other disease conditions as well. Here, LYZ is linked to early-onset autosomal dominant Alzheimer disease.